Evommune, Inc.
EVMNHealthcare|Biotechnology|US
$6.65
+0.28 (+4.40%)
Tangible Book / Share
$7.68
Cash / Share
$5.56
About
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Stock Price
-67.1%(1Y)
1M
+3.7%
3M
-52.8%
6M
-71.0%
YTD
-61.2%
1Y
-65.6%
3Y
-67.1%
5Y
-67.1%
Pipeline Summary
7 total trials0
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
Completed: 5Recruiting: 2
Active Trials (2)
Study of EVO756 in Adults With Migraine
NCT07616128Migraine
Phase 2Recruiting
Enrollment: 330 participants
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
NCT06645821Hidradenitis Suppurativa (HS)
Early P1Recruiting
Enrollment: 15 participants
Key Facts
Market Cap$241.3M
Employees55
CEOLuis C. Pena
IPO DateNov 6, 2025
Beta0.96
52-Week Range$4.94 – $33.2
Avg Volume767,233
ExchangeNYSE
Websiteevommune.com
Ownership
Float54.8%
Shares Outstanding36.3M
Recent Insider Trades
Pena Luis C.AWARD
Sep 30, 20261,115 shares @ $7.02
Carver KyleBUY
Jul 8, 20261,000 shares @ $13.26
KIRSCH ARTHUR SBUY
Jul 7, 202610,000 shares @ $13.30
Drew Janice SuzannOPTION EX.
Jun 22, 202616,161 shares @ $2.99
Drew Janice SuzannOPTION EX.
Jun 22, 20263,839 shares @ $3.84
Peers
Recent News
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
Nov 6, 2026 · marketbeat.com
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
Nov 6, 2026 · seekingalpha.com
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Nov 5, 2026 · businesswire.com
Evommune Announces $30 Million Private Placement
Nov 4, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:10 AM